Molecular structure of GP 1a, CAS Number: 511532-96-0
GP 1a (CAS 511532-96-0)
Alternate Names:
N-(Piperidin-1-yl)-1-(2,4-dichlorophenyl)-1,4-dihydro-6-methylindeno[1,2-c]pyrazole-3-carboxamide
Application:
GP 1a is a highly selective agonist of the CB2 cannabinoid receptors
CAS Number:
511532-96-0
Purity:
>99%
Molecular Weight:
441.35
Molecular Formula:
C23H22Cl2N4O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Available in US only.
Available in US only.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Highly selective CB2 agonist receptor; Ki values are 0.037 and 363 nM for CB2 and CB1 receptors respectively. Increases P-ERK1/2 expression in HL-60 cells in vitro.
GP 1a (CAS 511532-96-0) References
- Cannabinoid-induced enhanced interaction and protein levels of serotonin 5-HT(2A) and dopamine D₂ receptors in rat prefrontal cortex. | Franklin, JM. and Carrasco, GA. 2012. J Psychopharmacol. 26: 1333-47. PMID: 22791651
- Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling. | Franklin, JM. and Carrasco, GA. 2013. Synapse. 67: 145-59. PMID: 23151877
- Activation of type-2 cannabinoid receptor inhibits neuroprotective and antiinflammatory actions of glucocorticoid receptor α: when one is better than two. | Bisicchia, E., et al. 2013. Cell Mol Life Sci. 70: 2191-204. PMID: 23296125
- Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: a novel target for the attenuation of portal hypertension. | Steib, CJ., et al. 2013. Life Sci. 93: 543-51. PMID: 24007798
- Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. | Soethoudt, M., et al. 2017. Nat Commun. 8: 13958. PMID: 28045021
- Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn's Disease. | Leinwand, KL., et al. 2017. J Crohns Colitis. 11: 1369-1380. PMID: 28981653
- Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis. | Gado, F., et al. 2018. Medicines (Basel). 5: PMID: 30111755
- The Impact of Cannabinoid Receptor 2 Deficiency on Neutrophil Recruitment and Inflammation. | Hussain, MT., et al. 2019. DNA Cell Biol. 38: 1025-1029. PMID: 31532239
- Cannabinoid-Based Medicines and Multiple Sclerosis. | Manera, C. and Bertini, S. 2021. Adv Exp Med Biol. 1264: 111-129. PMID: 33332007
- Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation. | Osafo, N., et al. 2021. Mol Biol Rep. 48: 3665-3680. PMID: 33909195
- Medicinal Chemistry approach, pharmacology and neuroprotective benefits of CB2R modulators in neurodegenerative diseases. | Ferrisi, R., et al. 2021. Pharmacol Res. 170: 105607. PMID: 34089867
- Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease. | Wang, M., et al. 2022. Front Cell Neurosci. 16: 832854. PMID: 35264932
Activator of:
CB2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GP 1a, 10 mg | sc-203980 | 10 mg | $319.00 | |||
| US: Only available in the US | ||||||
GP 1a, 50 mg | sc-203980A | 50 mg | $1314.00 | |||
| US: Only available in the US | ||||||